Arrowhead Pharmaceuticals (ARWR) Receivables - Net (2010 - 2026)

Arrowhead Pharmaceuticals' Receivables - Net history runs 15 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• Quarterly Receivables - Net rose 563.21% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (up 563.21% YoY) and the FY2025 annual result came in at $6.8 million, changed N/A from the prior year.
• Receivables - Net was $15.7 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $218.4 million in the prior quarter.
• Across five years, Receivables - Net topped out at $218.4 million in Q4 2025 and bottomed at $239000.0 in Q2 2022.
• A 5-year average of $30.8 million and a median of $4.7 million in 2024 frame the typical range for Receivables - Net.
• Peak annual rise in Receivables - Net reached 26278.67% in 2022, while the deepest fall reached 86.25% in 2022.
• Arrowhead Pharmaceuticals' Receivables - Net stood at $39.6 million in 2022, then sank by 96.11% to $1.5 million in 2023, then surged by 62.44% to $2.5 million in 2024, then soared by 8634.16% to $218.4 million in 2025, then plunged by 92.82% to $15.7 million in 2026.
• Business Quant data shows ARWR's Receivables - Net at $15.7 million in Q1 2026, $218.4 million in Q4 2025, and $6.8 million in Q3 2025.